As noted earlier, JMP Securities downgraded BIND to Market Perform from Outperform. After the company's BIND-014 drug met its primary endpoint in a trial, the firm notes that the company intends to further develop BIND-014 in NSCLC. JMP removed revenue for BIND-014 in the setting of squamous NSCLC from its model until it receives further clarity regarding the company's development strategy for that program. JMP also noted that BIND decided to halt further enrollment in a trial of BIND-014 as a treatment for head and neck cancer and cervical cancer after patients with those diseases showed overall response rates of 10% and 0% respectively while taking BIND-014.